Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Oct 24 - Oct 29
Coverage unavailable when GLP-1 coverable under Part D benefit Beneficiaries who are prescribed Wegovy or Zepbound for a use that is coverable under the basic Medicare Part D benefit, regardless of whether the drug is on the Part D plans formulary (e.g., Zepbound for the treatment of moderate to severe obstructive sleep apnea in adults with obesity, or Wegovy to reduce the risk of major adverse cardiovascular (CV) events in adults with established CV disease who are either obese or overweight), will not qualify for coverage of that drug under the Bridge Program
Ozeki et al (2022) found that GLP1-RA semaglutide effectively reduces body adiposity while maintaining the skeletal muscle mass in obese Type 2 Diabetic patients. Xiang et al (2023) had similar findings, semaglutide can reduce the weight and fat of obese patients while effectively maintaining muscle mass and muscle strength. Chen et al (2023) conducted a 3-month intervention using dulaglutide in patients with Type 2 Diabetes, noting , dulaglutide intervention does not cause muscle and bone mass loss while inducing weight loss, and % change in body fat was independently associated with improved glucose control during dulaglutide therapy. With an increasing number of physicians and researchers relying on GLP-1 therapies for clinical care and research, it will continue to be crucial to track sensitive changes in body composition across different patient populations
No video visit is required up front
What are the benefits of component-based GLP-1 meal prep
The antioxidant response signals induce the activation of nuclear factor erythroid-derived 2-like-2 (Nrf2)
US$ 28.27
US$ 27.99
US$ 22.00
